The clinical-stage biopharmaceutical company has an experienced management team with over 50 years of combined drug development experience. Entera Bio focuses on developing and commercializing orally delivered large molecule therapeutics for areas with significant unmet medical needs. The company's product candidates, EB613 for osteoporosis and EB612 for hypoparathyroidism, are in clinical development. Entera Bio also licenses its technology to biopharmaceutical companies and has established collaborations with Amgen Inc. Their proprietary technology addresses the major problems of oral drug delivery of large molecule APIs by enhancing their absorption in the GI tract.